Govita Tech Limited (Govita) is pleased to announce that the US Patent Office has approved our new patent on March 21, 2023: Genetic and Metabolic Data-Associated Intervention (GMDAI®).
At Govita, we believe that personalized solutions for preventive medicine and healthy longevity are rooted in molecular tests to assess health and disease risks, artificial intelligence algorithms to correlate genotype and phenotype data, and intervention products to maintain the intracellular biomolecular homeostasis.
GMDAI® is an innovative, systematic and powerful tool that transforms our concepts into practice to meet people’s needs for healthy longevity. The system quickly analyzes and scientifically evaluates the functions of biological pathways in cells by testing genetic and metabolic biomarkers in selected biological pathways and applying intelligent algorithms to correlate the data, and generates personalized solutions. The intervention program maintains the homeostasis of intracellular biomolecular activities by regulating gene expression, metabolite levels, and signal transduction, thereby achieving our purpose of reducing disease risks, improving quality of life, and extending healthy lifespan.
Use GMDAI® patented technology to help us live a happy, healthy and long life!